Glioblastoma is a devastating disease and there is an urgent need to develop novel therapies such as oncolytic HSV1 (OV) to effectively target tumor cells. infiltration (Supplementary Figure S1b). CCN1 directly affects macrophage migration by binding integrin αMβ2toward uninfected or infected cancer cells. Using a modified Boyden Transwell assay we plated RAW264.7 macrophages in the top chamber and measured their migration toward infected LN229 glioblastoma cells plated in the bottom chamber. Figure 3a shows the experimental setup used. Consistent with the previous observations of increased macrophage infiltration in tumors treated with the oncolytic virus rHSVQ1 21 22 we found a significant increase in macrophage migration toward infected LN229 and U251T3 N-desMethyl EnzalutaMide glioblastoma cells compared with uninfected cells at multiple MOIs (Figure 3b ?cc; Supplementary Figure S2). To assess the effect of endogenously upregulated CCN1 on macrophage migration we measured the impact of using neutralizing anti-CCN1 antibodies on macrophage migration toward infected glioblastoma cells and and data show a trend toward improved antitumor response of OV-treated tumors in mice treated with anti-CCN1 blocking antibodies. To our knowledge this is the first study showing CCN1 can enhance the innate macrophage-mediated antiviral immune response playing a key role in orchestrating the destruction and clearance of disease causing pathogens in the body. CCN1 is a secreted extracellular matrix protein well known as an angiogenic inducer. While it has been shown to be involved in migration of various cancer cells its role in modulating immune responses is just beginning to be explored. Recently Bai et al identified CCN1 as a regulator of proinflammatory gene expression in murine macrophages.17 In that report treatment of macrophages with purified CCN1 for 1 6 and 24 hours resulted in enhanced inflammatory SERK1 gene expression with expression peaking at 6 hours. In addition it has been shown that CCN1 protein and over-expression of CCN1 in the liver contributes to a more severe hepatic inflammation and increases macrophage infiltrates.14 Here we examined the impact of secreted endogenous CCN1 on macrophage function N-desMethyl EnzalutaMide in the context of OV therapy for glioblastoma. Our study shows that increased production and secretion of CCN1 in the tumor microenvironment enhances macrophage activation and migration toward the site of inflammation by the direct interaction between CCN1 and integrin αMβ2 on the macrophage cell surface. While the ability for CCN1 to directly induce MCP-1 gene expression has been reported in endothelial progenitor cells and CD34+ progenitor cells 32 here we show that OV-induced CCN1 acts on macrophages through integrin αMβ2 enhancing their migration and also their proinflammatory activation. Activated macrophages in turn signal glioblastoma cells to secrete MCP-1 further enabling macrophage chemotaxis toward the site of infection. MCP-1 is a major player in the regulation of leukocyte trafficking and plays a key role in orchestrating the host defense response to HSV-1 infection.33 The activation and induced migration of macrophages by CCN1 ultimately results in reduced viral oncolysis of infected glioblastoma cells. One of the first lines of defense in the innate antiviral immune response to HSV-1 infection is the infiltration of effector cells such as macrophages NK cells and neutrophils. It is interesting to N-desMethyl EnzalutaMide note that while we show a significant role for CCN1 N-desMethyl EnzalutaMide in the infiltration of macrophages and NK cells toward infected glioblastoma cells we did not see an effect of CCN1 on neutrophil infiltration. While CCN1 is a known ligand for both macrophages and NK cells 13 14 its ability to bind neutrophils is yet unknown and our results suggest that it may not play a role in neutrophil chemotaxis toward HSV-1 infected brain tumors Human LN229 U251T2 U251T3 and Cy-1 glioblastoma cell lines were maintained N-desMethyl EnzalutaMide in Dulbecco’s modified minimal essential medium (DMEM) supplemented with 2% fetal bovine serum 100 penicillin and 100 μg/ml streptomycin. Mouse RAW264.7 macrophages and human THP-1 monocytes were maintained in RPMI medium supplemented with 5% fetal bovine serum 100 penicillin and 100 μg/ml streptomycin. We used rHSVQ1 and rHSVQ1-IE4/5-Luc HSV-1-derived recombinant oncolytic viruses which are.